Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00756964 · ClinicalTrials.gov registry record · Phase 2
Lowering Serum Uric Acid to Prevent Acute Kidney Injury
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00756964 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 26 participants.
The verdict
NCT00756964, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
Acute kidney injury is associated with a rise in serum uric acid during cardiovascular surgery and can cause poor blood flow to the kidneys making them vulnerable to kidney injury. We hypothesize that hyperuricemia, particularly if chronic and marked, is a risk factor for acute kidney injury. The preoperative lowering of serum uric acid will reduce the incidence of acute kidney injury following cardiovascular surgery.
Interventions
- DRUG Placebo
- DRUG Rasburicase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00756964
The ClinicalTrials.gov registry entry for NCT00756964 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00756964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00756964 about?
NCT00756964 is a clinical study titled "Lowering Serum Uric Acid to Prevent Acute Kidney Injury". Acute kidney injury is associated with a rise in serum uric acid during cardiovascular surgery and can cause poor blood flow to the kidneys making them vulnerable to kidney injury. We hypothesize that hyperuricemia, particularly if chronic and marked, is a risk factor for acute kidney injury. The pr...
What is the current status of trial NCT00756964?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-10. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00756964?
The interventions under investigation include: Placebo (DRUG), Rasburicase (DRUG).
Who is sponsoring clinical trial NCT00756964?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.